NAC Therapeutics

NAC Therapeutics is a preclinical-stage biotechnology company dedicated to developing first-in-class small molecule inhibitors of the Hedgehog signaling pathway. The company specifically targets GLI transcription factors, the downstream effectors of the pathway, to address cancers that have become resistant to traditional upstream inhibitors like vismodegib. Their lead research focuses on treating GLI-driven malignancies such as basal cell carcinoma and medulloblastoma. By inhibiting the terminal step of the pathway, NAC Therapeutics aims to provide more effective therapeutic options for patients with refractory solid tumors.